依奇珠单抗治疗中重度银屑病快速改善健康相关生活质量和瘙痒:UNCOVER-2和UNCOVER-3随机3期试验的事后分析
该事后分析汇总UNCOVER-2和UNCOVER-3随机试验中2570例中重度银屑病患者,比较依奇珠单抗每2周或每4周、依那西普和安慰剂治疗12周内健康相关生活质量和瘙痒的改善速度。结果显示依奇珠单抗组达到DLQI和瘙痒NRS最小临床重要差异的中位时间均短于依那西普和安慰剂组,差异有统计学意义。
要点
- 依奇珠单抗每2周或每4周组达到DLQI≥5分改善的中位时间均为2周,快于依那西普的4周和安慰剂的>12周。
- 依奇珠单抗组达到瘙痒NRS≥4分改善的中位时间均为2周,快于依那西普的8周和安慰剂的>12周。
- 依奇珠单抗较依那西普和安慰剂显著提高12周内达到DLQI或瘙痒MCID的可能性。
核心结论
- 依奇珠单抗治疗中重度银屑病患者在健康相关生活质量和瘙痒方面的改善速度显著快于依那西普和安慰剂。
研究设计与样本
- UNCOVER-2和UNCOVER-3随机试验的事后汇总分析,共纳入2570例患者:安慰剂361例、依那西普740例、依奇珠单抗每4周733例、每2周736例。
- 治疗12周,使用DLQI和瘙痒NRS评估,MCID分别定义为较基线改善≥5分和≥4分。
主要发现
- 依奇珠单抗每2周或每4周组达到DLQI≥5分改善的中位时间均为2周,依那西普组为4周,安慰剂组>12周。
- 依奇珠单抗每2周或每4周组达到瘙痒NRS≥4分改善的中位时间均为2周,依那西普组为8周,安慰剂组>12周。
- 依奇珠单抗组与依那西普和安慰剂组在达到DLQI或瘙痒NRS改善的时间上差异显著(P < 0.001)。
- 治疗12周后,依奇珠单抗组达到DLQI或瘙痒MCID的可能性显著高于依那西普和安慰剂组。
关键数值与推荐
- DLQI的MCID定义为较基线改善≥5分,瘙痒NRS的MCID定义为较基线改善≥4分。
临床怎么用
- 依奇珠单抗可在治疗2周内快速改善中重度银屑病患者的健康相关生活质量和瘙痒,优于依那西普和安慰剂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with moderate-to-severe psoriasis report impaired health-related quality of life (HRQoL). OBJECTIVE: To assess speed of onset of ixekizumab-induced clinically relevant improvement in HRQoL. METHODS: This post hoc analysis used pooled data from patients randomized in UNCOVER-2 and UNCOVER-3, and treated with 80 mg ixekizumab every 2 weeks (IXEQ2W), 80 mg ixekizumab every 4 weeks (IXEQ4W), 50 mg etanercept (ETN) twice weekly or placebo (PBO) for 12 weeks. HRQoL and pruritus were assessed using the Dermatology Life Quality Index (DLQI) and Itch Numeric Rating Scale (NRS), respectively. Minimally clinical important differences (MCID) in DLQI and Itch NRS were defined as ≥5-point and ≥4-point improvements from baseline, respectively. Time to response from randomization was estimated using Kaplan-Meier methodology and the log-rank test. Hazard ratios between treatments were calculated using a Cox proportional hazards regression model adjusting for studies. RESULTS: A total of 2570 patients were included: 361 PBO; 740 ETN; 733 IXEQ4W and 736 IXEQ2W. Significantly greater differences in time to DLQI ≥5 point or Itch NRS ≥4 point improvement for IXEQ2W or IXEQ4W compared with ETN and PBO (P < 0.001) were observed. The median time when 50% of patients reached a ≥5-point reduction in DLQI was shorter for ixekizumab-treated patients (2 weeks, both schedules) compared with ETN- (4 weeks) or PBO-treated (>12 weeks) patients. Likewise, the median time when 50% of patients reached a ≥4-point reduction in Itch NRS was shorter for ixekizumab-treated patients (2 weeks, both schedules) compared with ETN- (8 weeks) or PBO-treated (>12 weeks) patients. Significantly more ixekizumab-treated patients were likely to achieve MCIDs in DLQI or itch reduction compared with ETN or PBO after 12 weeks of treatment. CONCLUSION: Ixekizumab-treated patients achieved more rapid improvements both in HRQoL and itch compared with patients treated with ETN and PBO.
引用
- Leonardi CL, Blauvelt A, Sofen HL, et al. Rapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3. J Eur Acad Dermatol Venereol. 2017. PMID: 28294430. doi:10.1111/jdv.14211
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。